(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
75% of Arab Israelis support Arab party joining government coalition post-war, survey reveals - 2Select Your Go-To Bluetooth Earphones
- 3What is colostrum? And should you be taking it?
- 4Could the Star of Bethlehem have actually been a comet?
- 5Nuno Loureiro, MIT physicist, fatally shot at home; police investigate
- Nutrient Rich Organic products: Lift Your Wellbeing
- Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- Unsold Rams May Be Less expensive Than You Suspect
- How do my eyes adjust to the dark and how long does it take?
- Kennedy approves adding two rare disorders to newborn screenings
- Figure out How to Amplify the Resale Worth of Your Kona SUV
- 5 Must-Attempt Fascinating Dishes from Around the World
- Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
